A single laboratory value rarely tells the full story of diabetes control. Management depends on patterns over time, and a result that looks acceptable in isolation may sit inside a trend that deserves attention.
The HbA1c test provides a longer-term view of glycemia, while other results add information about current glucose control and diabetes-related health risks. Trend monitoring helps clinicians decide whether management is stable or whether further assessment is warranted.
HbA1c reflects average glycemia over approximately the previous 2 to 3 months. It is commonly used in ongoing diabetes management, and results should be assessed against each patient’s individualized treatment goals.
The American Diabetes Association identifies A1c as a primary tool for glycemic assessment in its 2026 Standards of Care. In practice, that makes the HbA1c test the anchor that other diabetes blood test results are read against.
Because HbA1c is an average, it does not capture day-to-day variability or episodes of hypoglycemia, so it is best read alongside glucose data.
A single value can mislead. Four patterns illustrate why longitudinal review is more informative:
Trends help clinicians assess treatment response, frame adherence discussions, decide whether medications need reassessment, and judge whether more monitoring is appropriate. They should not drive treatment decisions based on a specific number alone.
A gradual upward drift across three consecutive results, for example, may prompt an earlier review of therapy than any single value would.
Frequency should match the patient’s situation. HbA1c testing at least twice a year may be appropriate for patients with stable glycemic status who are meeting their goals.
Testing approximately every three months may be appropriate when treatment changes occur or glycemic goals are not being met. Clinical circumstances may call for a different schedule, and the interval should be documented so that future results can be compared consistently.
Standing orders with defined intervals help make sure the next HbA1c is drawn when it is due, rather than whenever a visit happens to occur.
Other results complete the picture. Fasting or other plasma glucose measurements provide a more immediate snapshot, and they are most useful alongside longer-term HbA1c trends. Related testing may include:
Not every marker is necessary for every person with diabetes. The goal is to choose the tests that answer the patient’s current clinical questions.
Discordance should prompt clinical review rather than assumptions. ADA advises clinicians to investigate substantial differences between glucose measurements and A1c results.
Factors that can affect HbA1c reliability include altered red blood cell turnover, certain hemoglobin variants, recent blood loss or transfusion, some anemias, and other conditions that interfere with the assay.
When a mismatch appears, comparing home glucose or CGM data with laboratory values can help clarify which result better reflects the patient’s status. Documenting the discordance in the record also helps the next reviewer interpret later values.
A trend only exists if results can be compared. Use consistent testing intervals when clinically appropriate, and review prior values alongside current findings. Flag meaningful changes so they are not lost between visits, especially when more than one clinician reviews the same patient.
Combine laboratory data with medications, symptoms, home glucose or CGM findings, and comorbidities. Keeping longitudinal results accessible within the patient’s record turns routine blood testing into usable clinical context.
Trend monitoring depends on dependable logistics. Timely ordering, reliable specimen collection, consistent reporting, and easy access to prior results all affect whether a trend can be spotted. EMR integration helps keep those results in one place.
Coordination matters most for patients with mobility limitations, where mobile phlebotomy for home health agencies can keep scheduled testing on track. In long-term care, the same discipline applies to standing orders and consistent draw schedules.
Diabetes monitoring is built from repeated, reliable testing. PSC Dx supports routine and ongoing monitoring through clinical bloodwork, mobile phlebotomy, and EMR integration, including HbA1c and related diabetes testing for primary care, long-term care, and home health settings.
For organizations managing many patients with diabetes, dependable collection and consistent reporting make trends easier to see and results easier to act on, whether the patient is seen in a clinic, a facility, or at home.
Contact PSC Dx to discuss routine and ongoing laboratory support for diabetes management in your practice or facility.
It reflects average blood glucose over approximately the previous 2 to 3 months.
At least twice a year when control is stable and goals are met, and about every three months when therapy changes or goals are not met.
Conditions such as altered red blood cell turnover, hemoglobin variants, recent blood loss or transfusion, and some anemias can affect HbA1c reliability.
Plasma glucose, kidney function tests, and lipid panels are commonly tracked, along with other tests when clinically indicated.
